Sonoval
Sonoval is developing novel anticancer therapies for lymphomas and solid tumors that work in two ways:
- Destroying cancers by binding to receptors on tumor cells and delivering a toxic payload.
- Eliminating immune system suppressors, unleashing the patient's own anticancer defenses.
Sonoval's protein-based anticancer drug candidates, including SON-211 and others, are each engineered to minimize potential side-effects and are manufactured using proprietary expression technology.
Contact Name:
Peter Suzdak, PhD
Chief Executive Officer
Address:
801 W. Baltimore St.
Suite 502L
Baltimore Maryland 21201
United States